search
Back to results

Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) (EVOLUTION)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 2
Locations
Brazil
Study Type
Interventional
Intervention
Evogliptin
Sitagliptin
Placebo Evogliptin
Placebo Sitagliptin
Sponsored by
Eurofarma Laboratorios S.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes Mellitus Type 2

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female patients meeting all the following criteria will be enrolled in the study:

    1. Aged between 20 and 75 years old.
    2. Diagnosis of T2DM according to the criteria of the American Diabetes Association (ADA).
    3. Not having received treatment with oral hypoglycemic agents or insulin within 12 weeks prior to the screening visit;
    4. Glycated hemoglobin (HbA1c) levels at the screening visit of 7.5% ≤ HbA1c ≤ 10.5%, after appropriate treatment with diet and physical exercise for ≥ 12 weeks;
    5. Body mass index (BMI) of 20 kg/m2 ≤ BMI ≤ 40 kg/m2 at the screening visit.
    6. Signing the Informed Consent Form (ICF) before the performance of any study procedure.

Exclusion Criteria:

- Patients meeting at least one of the following criteria will be excluded from the study:

  1. Fasting blood glucose values > 300 mg/dL with severe clinical manifestations present (significant loss weight, severe symptoms and/or ketonuria).
  2. Current participation in weight loss programs, with or without anti-obesity drugs use.
  3. Presence of heart failure functional class III or IV according to the New York Heart Association (NYHA).
  4. Presence of symptomatic liver or gall bladder disease.
  5. History of myocardial infarction, transient ischemic attack or coronary angioplasty within 6 months prior to the screening visit.
  6. History of gastrointestinal resection.
  7. Estimated creatinine clearance (Cockroft and Gault formula) < 60 mL/min.
  8. Serum ALT and/or AST level ≥ 2.5 x upper normal limit.
  9. Serum CPK level ≥ 3 x upper normal limit.
  10. Fasting triglycerides > 400 mg/dL.
  11. History of major skin allergy.
  12. Use of corticosteroids within 3 months prior to the screening visit.
  13. Concomitant treatment with warfarin, dicoumarinic agents or digoxin.
  14. Concomitant use of drugs or foods that interfere with the CYP3A4 pathway of liver metabolism including, but not limited to:

    • Inhibitors: antibacterial agents (erythromycin), antifungals (itraconazole, ketoconazole), antivirals (ritonavir, saquinavir, amprenavir, indinavir, nelfinavir), H2 receptor antagonists (cimetidine) and grapefruit juice;
    • Inducers: dexamethasone, rifampin and anticonvulsants (phenytoin, phenobarbital, carbamazepine)
  15. History of untreated or uncontrolled thyroid disorder.
  16. History of drugs of abuse or moderate/heavy alcohol consumption within 2 months prior to screening.
  17. Presence of severe or uncontrolled diseases.
  18. Presence of pregnancy or breastfeeding.
  19. Women of childbearing potential who do not agree to use a proven effective contraceptive method, unless they are surgically sterile or declare being expressly exempt of pregnancy risk for not engaging in sexual practices or for engaging in them in a non-reproductive manner.
  20. Participation in a clinical trial protocol within the previous 12 months unless, at the investigator's discretion, his or her participation may imply a direct benefit for the participant.
  21. Presence of any condition which, at the investigator's discretion, may render the patient inadequate for study participation.

Sites / Locations

  • Centro de Estudos em Diabetes e Hipertensão
  • Hospital Universitário João de Barros Barreto - HUJBB
  • CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda
  • Centro de Pesquisa Clínica em Diabetes - UNIFESP
  • CEPIC - Centro Paulista de Investigação Clínica
  • Clinica de Endocrinologia e Metabologia LTDA
  • CPCLIN - Centro de Pesquisas Clinicas LTDA
  • HCFMUSP
  • IMA - Instituto de Pesquisa Clínica e Medicina Avançada Ltda
  • IPEC - Instituto de Pesquisa Clínica Ltda

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Evogliptin 2.5mg+Placebo Sitagliptin

Evogliptin 5.0mg+Placebo Sitagliptin

Evogliptin 10.0mg+Placebo Sitagliptin

Sitagliptin 100mg+Placebo Evogliptin

Arm Description

Evogliptin (EVO) will be administered orally at a daily dose of: 2.5 mg. The participants randomized to this group will receive 1 tablet daily of EVO 2.5 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.

Evogliptin (EVO) will be administered orally at a daily dose of: 5.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 5.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.

Evogliptin (EVO) will be administered orally at a daily dose of: 10.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 10.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.

SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.

Outcomes

Primary Outcome Measures

Absolute variation of the values obtained in the baseline for the HbA1c

Secondary Outcome Measures

Absolute variation of the values obtained in the baseline for the parameter, fasting blood glucose.
Absolute variation of the values obtained in the baseline for the parameter, body weight.

Full Information

First Posted
February 10, 2016
Last Updated
August 12, 2018
Sponsor
Eurofarma Laboratorios S.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT02689362
Brief Title
Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)
Acronym
EVOLUTION
Official Title
A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Clinical Trial for the Validation of Optimum Dose and Preliminary Evaluation of Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
August 8, 2017 (Actual)
Primary Completion Date
August 9, 2018 (Actual)
Study Completion Date
August 9, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eurofarma Laboratorios S.A.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This phase II, multicenter, randomized, double-blind, double-dummy study with four parallel treatment groups, with active control, will be performed only in brazilian sites under the sponsorship of Eurofarma Laboratórios S.A.. The enrollment for participants in the study will start after the relevant ethical and regulatory approvals and will have an estimated duration of 18 months. One hundred and forty-four participants with T2DM according to the criteria of ADA who consent to participation in the study by signing the Informed Consent Form (ICF) will be enrolled in the study. In order to be enrolled, the patients must meet all the inclusion criteria and none of the exclusion criteria. The eligible participants will be randomized 1:1:1:1 to receive evogliptin (EVO) at the doses of 2.5 mg/day (N = 36), 5.0 mg/day (N = 36) or 10 mg/day (N = 36) or sitagliptin (SITA) at the dose of 100 mg/day (N = 36), as a single daily dose, for 12 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Diabetes Mellitus Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
146 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Evogliptin 2.5mg+Placebo Sitagliptin
Arm Type
Experimental
Arm Description
Evogliptin (EVO) will be administered orally at a daily dose of: 2.5 mg. The participants randomized to this group will receive 1 tablet daily of EVO 2.5 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
Arm Title
Evogliptin 5.0mg+Placebo Sitagliptin
Arm Type
Experimental
Arm Description
Evogliptin (EVO) will be administered orally at a daily dose of: 5.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 5.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
Arm Title
Evogliptin 10.0mg+Placebo Sitagliptin
Arm Type
Experimental
Arm Description
Evogliptin (EVO) will be administered orally at a daily dose of: 10.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 10.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
Arm Title
Sitagliptin 100mg+Placebo Evogliptin
Arm Type
Active Comparator
Arm Description
SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Evogliptin
Intervention Description
1 tablet per day
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Intervention Description
1 tablet per day
Intervention Type
Drug
Intervention Name(s)
Placebo Evogliptin
Intervention Description
1 tablet per day
Intervention Type
Drug
Intervention Name(s)
Placebo Sitagliptin
Intervention Description
1 tablet per day
Primary Outcome Measure Information:
Title
Absolute variation of the values obtained in the baseline for the HbA1c
Time Frame
12 weeks after the start of the treatment
Secondary Outcome Measure Information:
Title
Absolute variation of the values obtained in the baseline for the parameter, fasting blood glucose.
Time Frame
12 weeks after the start of the treatment
Title
Absolute variation of the values obtained in the baseline for the parameter, body weight.
Time Frame
12 weeks after the start of the treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients meeting all the following criteria will be enrolled in the study: Aged between 20 and 75 years old. Diagnosis of T2DM according to the criteria of the American Diabetes Association (ADA). Not having received treatment with oral hypoglycemic agents or insulin within 12 weeks prior to the screening visit; Glycated hemoglobin (HbA1c) levels at the screening visit of 7.5% ≤ HbA1c ≤ 10.5%, after appropriate treatment with diet and physical exercise for ≥ 12 weeks; Body mass index (BMI) of 20 kg/m2 ≤ BMI ≤ 40 kg/m2 at the screening visit. Signing the Informed Consent Form (ICF) before the performance of any study procedure. Exclusion Criteria: - Patients meeting at least one of the following criteria will be excluded from the study: Fasting blood glucose values > 300 mg/dL with severe clinical manifestations present (significant loss weight, severe symptoms and/or ketonuria). Current participation in weight loss programs, with or without anti-obesity drugs use. Presence of heart failure functional class III or IV according to the New York Heart Association (NYHA). Presence of symptomatic liver or gall bladder disease. History of myocardial infarction, transient ischemic attack or coronary angioplasty within 6 months prior to the screening visit. History of gastrointestinal resection. Estimated creatinine clearance (Cockroft and Gault formula) < 60 mL/min. Serum ALT and/or AST level ≥ 2.5 x upper normal limit. Serum CPK level ≥ 3 x upper normal limit. Fasting triglycerides > 400 mg/dL. History of major skin allergy. Use of corticosteroids within 3 months prior to the screening visit. Concomitant treatment with warfarin, dicoumarinic agents or digoxin. Concomitant use of drugs or foods that interfere with the CYP3A4 pathway of liver metabolism including, but not limited to: Inhibitors: antibacterial agents (erythromycin), antifungals (itraconazole, ketoconazole), antivirals (ritonavir, saquinavir, amprenavir, indinavir, nelfinavir), H2 receptor antagonists (cimetidine) and grapefruit juice; Inducers: dexamethasone, rifampin and anticonvulsants (phenytoin, phenobarbital, carbamazepine) History of untreated or uncontrolled thyroid disorder. History of drugs of abuse or moderate/heavy alcohol consumption within 2 months prior to screening. Presence of severe or uncontrolled diseases. Presence of pregnancy or breastfeeding. Women of childbearing potential who do not agree to use a proven effective contraceptive method, unless they are surgically sterile or declare being expressly exempt of pregnancy risk for not engaging in sexual practices or for engaging in them in a non-reproductive manner. Participation in a clinical trial protocol within the previous 12 months unless, at the investigator's discretion, his or her participation may imply a direct benefit for the participant. Presence of any condition which, at the investigator's discretion, may render the patient inadequate for study participation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Suely K Inoue, Pharm D
Organizational Affiliation
Eurofarma Laboratórios S/A
Official's Role
Study Chair
Facility Information:
Facility Name
Centro de Estudos em Diabetes e Hipertensão
City
Fortaleza
State/Province
Ceará
Country
Brazil
Facility Name
Hospital Universitário João de Barros Barreto - HUJBB
City
Belém
State/Province
Pará
Country
Brazil
Facility Name
CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda
City
Rio de Janeiro
Country
Brazil
Facility Name
Centro de Pesquisa Clínica em Diabetes - UNIFESP
City
São Paulo
Country
Brazil
Facility Name
CEPIC - Centro Paulista de Investigação Clínica
City
São Paulo
Country
Brazil
Facility Name
Clinica de Endocrinologia e Metabologia LTDA
City
São Paulo
Country
Brazil
Facility Name
CPCLIN - Centro de Pesquisas Clinicas LTDA
City
São Paulo
Country
Brazil
Facility Name
HCFMUSP
City
São Paulo
Country
Brazil
Facility Name
IMA - Instituto de Pesquisa Clínica e Medicina Avançada Ltda
City
São Paulo
Country
Brazil
Facility Name
IPEC - Instituto de Pesquisa Clínica Ltda
City
São Paulo
Country
Brazil

12. IPD Sharing Statement

Citations:
PubMed Identifier
31890041
Citation
Cercato C, Felicio JS, Russo LAT, Borges JLC, Salles J, Muskat P, Bonansea T, Chacra AR, Eliaschewitz FG, Forti AC. Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study. Diabetol Metab Syndr. 2019 Dec 19;11:107. doi: 10.1186/s13098-019-0505-z. eCollection 2019.
Results Reference
derived

Learn more about this trial

Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)

We'll reach out to this number within 24 hrs